Stimulant Use Disorders

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.

This was a virtual public workshop to discuss a practical research agenda toward treatment development for stimulant use disorder. Meeting participants responded to a proposed practical research agenda that focuses on innovation in clinical trial design and candidate endpoints for the evaluation of potential treatments for stimulant use disorder.

This was a two-day virtual public workshop (which can now be re-watched) that focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).

This was a two-day virtual public workshop (which can now be re-watched) that convened regulators, clinical researchers, providers, patient advocates, and other stakeholders to exchange information and obtain input by discussing prescriber education's potential role in alleviating the evolving opioid and substance use crisis.

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.

Based on 2020 and earlier NSDUH data, this report contains findings on a wide variety of key substance use and mental health indicators in the United States.

A fact sheet which outlines new strategies that can reduce the risks from polysubstance use.

A summary of a workshop from the National Institutes of Health (NIH) HEAL (Helping to End Addiction Long-Term) Initiative, discussing opioid use in the context of polysubstance use.

This brief examines the prevalence of diagnoses of polysubstance use disorders, describes the characteristics of Medicaid enrollees with polysubstance use disorders, and compares the mental health and medical comorbidities based on the number of unique substance use disorders.

A Practice Guideline which includes treatment recommendations for patients with substance use disorders, as well as background information and a review of available evidence.